Enalaprilat injection is used in the management of hypertension when oral therapy is not practical. Enalaprilat is the active metabolite of the oral prodrug enalapril maleate. Enalaprilat is poorly absorbed orally and requires intravenous administration. It inhibits angiotensin I to angiotensin II conversion via competitive inhibition of the angiotensin-converting enzyme (ACE). This activity
Enalaprilat is the active metabolite of the oral prodrug enalapril maleate. Enalaprilat is poorly absorbed orally and requires intravenous administration. It inhibits angiotensin I to angiotensin II conversion via competitive inhibition of the angiotensin-converting enzyme (ACE).
Fosinoprilat, enalaprilat and lisinopril pharmacokinetics proportional to the concentration of fosinoprilat, enalapri-Results lat or lisinopril. CoeYcients of variation ranged from 2.0% to 8.8% and from 6.3% to 14.2% in the fosinoprilat-Demographics enalaprilat and the fosinoprilat-lisinopril studies, respect-
Drug Interactions Aliskiren Benazepril Captopril Enalapril Enalaprilat Fosinopril Lisinopril Moexipril
benazepril (Lotensin); captopril; enalapril (Vasotec); enalaprilat; fosinopril; lisinopril (Zestril and Prinivil); moexipril; perindopril
benazepril (Lotensin) captopril enalapril (Vasotec) enalaprilat fosinopril lisinopril (Zestril and Prinivil) moexipril perindopril
ACE inhibitors, snake venom peptide, bioisosterism, antihypertensive agents lisinopril, which had. comparable potency to enalaprilat. Lisinopril is more.
Enalaprilat injection is used in the management of hypertension when oral therapy is not practical. Enalaprilat is the active metabolite of the oral prodrug enalapril maleate. Enalaprilat is poorly absorbed orally and requires intravenous administration. It inhibits angiotensin I to angiotensin II conversion via competitive inhibition of the angiotensin-converting enzyme (ACE). This activity
conversion to enalaprilat, there is no evidence of significant metabolism of enalapril. as angiotensin converting enzyme (ACE) inhibitors.
Comments